Oxford Biomedica

Oxford Biomedica PLC, a company in the Biological Product (except Diagnostic) Manufacturing industry headquartered in GB, reported a total of approximately 66.3 billion kg CO2e in 2025. This total is comprised of approximately 2.4 million kg CO2e for Scope 1 emissions, approximately 1.3 million kg CO2e for Scope 2 emissions (market-based), and approximately 62.5 million kg CO2e for Scope 3 emissions.

For 2024, the company's total emissions were approximately 83.9 billion kg CO2e, with Scope 1 at approximately 2.4 million kg CO2e, Scope 2 (market-based) at approximately 1.7 million kg CO2e, and Scope 3 at approximately 79.8 billion kg CO2e.

In 2023, Oxford Biomedica reported total emissions of approximately 57.6 billion kg CO2e, consisting of approximately 3.4 million kg CO2e for Scope 1, approximately 1.5 million kg CO2e for Scope 2 (market-based), and approximately 52.7 billion kg CO2e for Scope 3.

Climate Commitments and Reduction Targets:

Oxford Biomedica has established ambitious climate targets. The company is committed to achieving a 42% absolute reduction in Scope 1 and 2 greenhouse gas emissions by 2030, using 2021 as a baseline year. This target aligns with the 1.5°C pathway. Furthermore, they aim to increase their active annual sourcing of renewable electricity from 29.1% in 2021 to 100% by 2030. They also commit that 90% of their suppliers by emissions, covering purchased goods and services, will have science-based targets by 2029.

In the near term, Oxford Biomedica is focused on cutting direct operational emissions by more than 6% and achieving a cumulative reduction of nearly 40% against its 2021 baseline. This puts them on track to meet their goal of reducing Scope 1 and 2 emissions by 42% in absolute terms by 2030.

The company's commitment to science-based targets is also evident, with a near-term target set for 2030 and a long-term net-zero commitment aligned with a 2023 base year extending to 2050.